Assertio Holdings, Inc.
Assertio Holdings, Inc. (ASRT) Stock Competitors & Peer Comparison
See (ASRT) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ASRT | $0.79 | +2.05% | 75.6M | -1.75 | -$0.45 | N/A |
| ZTS | $156.62 | +0.65% | 69.4B | 26.90 | $5.82 | +1.23% |
| TAK | $15.52 | +1.37% | 49B | 53.50 | $0.29 | +3.89% |
| HLN | $9.82 | +0.10% | 44.6B | 21.78 | $0.45 | +1.79% |
| TEVA | $18.46 | -1.81% | 21.2B | -123.13 | -$0.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $135.43 | +0.11% | 13.4B | 40.07 | $3.38 | N/A |
| VTRS | $10.65 | -0.37% | 12.4B | -3.63 | -$2.93 | +4.47% |
| RDY | $14.51 | +0.62% | 12.1B | 18.61 | $0.78 | +0.63% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
Stock Comparison
ASRT vs ZTS Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, ZTS has a market cap of 69.4B. Regarding current trading prices, ASRT is priced at $0.79, while ZTS trades at $156.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas ZTS's P/E ratio is 26.90. In terms of profitability, ASRT's ROE is -0.38%, compared to ZTS's ROE of +0.53%. Regarding short-term risk, ASRT is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check ZTS's competition here
ASRT vs TAK Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, TAK has a market cap of 49B. Regarding current trading prices, ASRT is priced at $0.79, while TAK trades at $15.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas TAK's P/E ratio is 53.50. In terms of profitability, ASRT's ROE is -0.38%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ASRT is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check TAK's competition here
ASRT vs HLN Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, HLN has a market cap of 44.6B. Regarding current trading prices, ASRT is priced at $0.79, while HLN trades at $9.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas HLN's P/E ratio is 21.78. In terms of profitability, ASRT's ROE is -0.38%, compared to HLN's ROE of +0.09%. Regarding short-term risk, ASRT is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check HLN's competition here
ASRT vs TEVA Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, TEVA has a market cap of 21.2B. Regarding current trading prices, ASRT is priced at $0.79, while TEVA trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas TEVA's P/E ratio is -123.13. In terms of profitability, ASRT's ROE is -0.38%, compared to TEVA's ROE of -0.03%. Regarding short-term risk, ASRT is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check TEVA's competition here
ASRT vs ITCI Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ASRT is priced at $0.79, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ASRT's ROE is -0.38%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, ASRT is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check ITCI's competition here
ASRT vs NBIX Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, NBIX has a market cap of 13.4B. Regarding current trading prices, ASRT is priced at $0.79, while NBIX trades at $135.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas NBIX's P/E ratio is 40.07. In terms of profitability, ASRT's ROE is -0.38%, compared to NBIX's ROE of +0.13%. Regarding short-term risk, ASRT is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check NBIX's competition here
ASRT vs VTRS Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, VTRS has a market cap of 12.4B. Regarding current trading prices, ASRT is priced at $0.79, while VTRS trades at $10.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas VTRS's P/E ratio is -3.63. In terms of profitability, ASRT's ROE is -0.38%, compared to VTRS's ROE of -0.20%. Regarding short-term risk, ASRT is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check VTRS's competition here
ASRT vs RDY Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, RDY has a market cap of 12.1B. Regarding current trading prices, ASRT is priced at $0.79, while RDY trades at $14.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas RDY's P/E ratio is 18.61. In terms of profitability, ASRT's ROE is -0.38%, compared to RDY's ROE of +0.17%. Regarding short-term risk, ASRT is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check RDY's competition here
ASRT vs CTLT Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ASRT is priced at $0.79, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ASRT's ROE is -0.38%, compared to CTLT's ROE of -0.06%. Regarding short-term risk, ASRT is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check CTLT's competition here
ASRT vs ELAN Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, ELAN has a market cap of 8.9B. Regarding current trading prices, ASRT is priced at $0.79, while ELAN trades at $17.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas ELAN's P/E ratio is 20.35. In terms of profitability, ASRT's ROE is -0.38%, compared to ELAN's ROE of +0.07%. Regarding short-term risk, ASRT is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check ELAN's competition here
ASRT vs RGC Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, RGC has a market cap of 6.3B. Regarding current trading prices, ASRT is priced at $0.79, while RGC trades at $12.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas RGC's P/E ratio is -1280.00. In terms of profitability, ASRT's ROE is -0.38%, compared to RGC's ROE of -0.50%. Regarding short-term risk, ASRT is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check RGC's competition here
ASRT vs LNTH Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, LNTH has a market cap of 4B. Regarding current trading prices, ASRT is priced at $0.79, while LNTH trades at $58.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas LNTH's P/E ratio is 15.48. In terms of profitability, ASRT's ROE is -0.38%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, ASRT is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check LNTH's competition here
ASRT vs PRGO Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, PRGO has a market cap of 3.4B. Regarding current trading prices, ASRT is priced at $0.79, while PRGO trades at $24.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas PRGO's P/E ratio is -56.94. In terms of profitability, ASRT's ROE is -0.38%, compared to PRGO's ROE of -0.02%. Regarding short-term risk, ASRT is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check PRGO's competition here
ASRT vs INDV Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, INDV has a market cap of 3B. Regarding current trading prices, ASRT is priced at $0.79, while INDV trades at $24.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas INDV's P/E ratio is 30.02. In terms of profitability, ASRT's ROE is -0.38%, compared to INDV's ROE of -0.48%. Regarding short-term risk, ASRT is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check INDV's competition here
ASRT vs AMRX Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, AMRX has a market cap of 3B. Regarding current trading prices, ASRT is priced at $0.79, while AMRX trades at $9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas AMRX's P/E ratio is 959.00. In terms of profitability, ASRT's ROE is -0.38%, compared to AMRX's ROE of -0.03%. Regarding short-term risk, ASRT is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check AMRX's competition here
ASRT vs HCM Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, HCM has a market cap of 2.8B. Regarding current trading prices, ASRT is priced at $0.79, while HCM trades at $16.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas HCM's P/E ratio is 6.08. In terms of profitability, ASRT's ROE is -0.38%, compared to HCM's ROE of +0.05%. Regarding short-term risk, ASRT is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check HCM's competition here
ASRT vs BHC Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, BHC has a market cap of 2.8B. Regarding current trading prices, ASRT is priced at $0.79, while BHC trades at $7.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas BHC's P/E ratio is 28.81. In terms of profitability, ASRT's ROE is -0.38%, compared to BHC's ROE of -0.09%. Regarding short-term risk, ASRT is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check BHC's competition here
ASRT vs ALVO Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, ALVO has a market cap of 2.6B. Regarding current trading prices, ASRT is priced at $0.79, while ALVO trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas ALVO's P/E ratio is 36.74. In terms of profitability, ASRT's ROE is -0.38%, compared to ALVO's ROE of -0.21%. Regarding short-term risk, ASRT is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check ALVO's competition here
ASRT vs SUPN Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, ASRT is priced at $0.79, while SUPN trades at $44.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas SUPN's P/E ratio is 39.03. In terms of profitability, ASRT's ROE is -0.38%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, ASRT is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check SUPN's competition here
ASRT vs ALVOW Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, ALVOW has a market cap of 2.5B. Regarding current trading prices, ASRT is priced at $0.79, while ALVOW trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas ALVOW's P/E ratio is N/A. In terms of profitability, ASRT's ROE is -0.38%, compared to ALVOW's ROE of -0.21%. Regarding short-term risk, ASRT is more volatile compared to ALVOW. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check ALVOW's competition here
ASRT vs DCPH Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ASRT is priced at $0.79, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ASRT's ROE is -0.38%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ASRT is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check DCPH's competition here
ASRT vs ANIP Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, ANIP has a market cap of 2B. Regarding current trading prices, ASRT is priced at $0.79, while ANIP trades at $91.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas ANIP's P/E ratio is -131.90. In terms of profitability, ASRT's ROE is -0.38%, compared to ANIP's ROE of -0.03%. Regarding short-term risk, ASRT is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check ANIP's competition here
ASRT vs EMBCV Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ASRT is priced at $0.79, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ASRT's ROE is -0.38%, compared to EMBCV's ROE of +0.71%. Regarding short-term risk, ASRT is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check EMBCV's competition here
ASRT vs TARO Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ASRT is priced at $0.79, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas TARO's P/E ratio is 30.05. In terms of profitability, ASRT's ROE is -0.38%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ASRT is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check TARO's competition here
ASRT vs BGM Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, BGM has a market cap of 1.5B. Regarding current trading prices, ASRT is priced at $0.79, while BGM trades at $8.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas BGM's P/E ratio is -26.41. In terms of profitability, ASRT's ROE is -0.38%, compared to BGM's ROE of -0.03%. Regarding short-term risk, ASRT is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check BGM's competition here
ASRT vs AVDL Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, AVDL has a market cap of 1.5B. Regarding current trading prices, ASRT is priced at $0.79, while AVDL trades at $15.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas AVDL's P/E ratio is -762.00. In terms of profitability, ASRT's ROE is -0.38%, compared to AVDL's ROE of -0.04%. Regarding short-term risk, ASRT is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check AVDL's competition here
ASRT vs HROW Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, ASRT is priced at $0.79, while HROW trades at $39.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas HROW's P/E ratio is -139.71. In terms of profitability, ASRT's ROE is -0.38%, compared to HROW's ROE of -0.18%. Regarding short-term risk, ASRT is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check HROW's competition here
ASRT vs AMPH Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, AMPH has a market cap of 1.4B. Regarding current trading prices, ASRT is priced at $0.79, while AMPH trades at $30.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas AMPH's P/E ratio is 11.42. In terms of profitability, ASRT's ROE is -0.38%, compared to AMPH's ROE of +0.18%. Regarding short-term risk, ASRT is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check AMPH's competition here
ASRT vs PAHC Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, PAHC has a market cap of 1.3B. Regarding current trading prices, ASRT is priced at $0.79, while PAHC trades at $32.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas PAHC's P/E ratio is 41.62. In terms of profitability, ASRT's ROE is -0.38%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, ASRT is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check PAHC's competition here
ASRT vs EVO Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, EVO has a market cap of 1.3B. Regarding current trading prices, ASRT is priced at $0.79, while EVO trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas EVO's P/E ratio is -7.14. In terms of profitability, ASRT's ROE is -0.38%, compared to EVO's ROE of -0.17%. Regarding short-term risk, ASRT is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check EVO's competition here
ASRT vs TLRY Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, TLRY has a market cap of 1.3B. Regarding current trading prices, ASRT is priced at $0.79, while TLRY trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas TLRY's P/E ratio is -0.47. In terms of profitability, ASRT's ROE is -0.38%, compared to TLRY's ROE of -0.78%. Regarding short-term risk, ASRT is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check TLRY's competition here
ASRT vs COLL Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, COLL has a market cap of 1.2B. Regarding current trading prices, ASRT is priced at $0.79, while COLL trades at $39.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas COLL's P/E ratio is 36.90. In terms of profitability, ASRT's ROE is -0.38%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ASRT is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check COLL's competition here
ASRT vs DVAX Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, DVAX has a market cap of 1.2B. Regarding current trading prices, ASRT is priced at $0.79, while DVAX trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas DVAX's P/E ratio is -23.33. In terms of profitability, ASRT's ROE is -0.38%, compared to DVAX's ROE of -0.09%. Regarding short-term risk, ASRT is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check DVAX's competition here
ASRT vs PCRX Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, PCRX has a market cap of 1.2B. Regarding current trading prices, ASRT is priced at $0.79, while PCRX trades at $25.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas PCRX's P/E ratio is -9.40. In terms of profitability, ASRT's ROE is -0.38%, compared to PCRX's ROE of -0.17%. Regarding short-term risk, ASRT is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check PCRX's competition here
ASRT vs CRON Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, CRON has a market cap of 995.6M. Regarding current trading prices, ASRT is priced at $0.79, while CRON trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas CRON's P/E ratio is 52.00. In terms of profitability, ASRT's ROE is -0.38%, compared to CRON's ROE of +0.02%. Regarding short-term risk, ASRT is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check CRON's competition here
ASRT vs PETQ Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ASRT is priced at $0.79, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ASRT's ROE is -0.38%, compared to PETQ's ROE of +0.12%. Regarding short-term risk, ASRT is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check PETQ's competition here
ASRT vs EMBC Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, EMBC has a market cap of 841M. Regarding current trading prices, ASRT is priced at $0.79, while EMBC trades at $14.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas EMBC's P/E ratio is 10.13. In terms of profitability, ASRT's ROE is -0.38%, compared to EMBC's ROE of -0.11%. Regarding short-term risk, ASRT is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check EMBC's competition here
ASRT vs SIGA Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, SIGA has a market cap of 653.8M. Regarding current trading prices, ASRT is priced at $0.79, while SIGA trades at $9.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas SIGA's P/E ratio is 8.01. In terms of profitability, ASRT's ROE is -0.38%, compared to SIGA's ROE of +0.41%. Regarding short-term risk, ASRT is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check SIGA's competition here
ASRT vs ORGO Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, ORGO has a market cap of 620.3M. Regarding current trading prices, ASRT is priced at $0.79, while ORGO trades at $4.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas ORGO's P/E ratio is -34.93. In terms of profitability, ASRT's ROE is -0.38%, compared to ORGO's ROE of -0.03%. Regarding short-term risk, ASRT is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check ORGO's competition here
ASRT vs SNDL Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, SNDL has a market cap of 579.1M. Regarding current trading prices, ASRT is priced at $0.79, while SNDL trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas SNDL's P/E ratio is -8.33. In terms of profitability, ASRT's ROE is -0.38%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, ASRT is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check SNDL's competition here
ASRT vs BDSI Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ASRT is priced at $0.79, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ASRT's ROE is -0.38%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ASRT is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check BDSI's competition here
ASRT vs EOLS Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, EOLS has a market cap of 496.8M. Regarding current trading prices, ASRT is priced at $0.79, while EOLS trades at $7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas EOLS's P/E ratio is -7.92. In terms of profitability, ASRT's ROE is -0.38%, compared to EOLS's ROE of +17.91%. Regarding short-term risk, ASRT is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check EOLS's competition here
ASRT vs EBS Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, EBS has a market cap of 493.2M. Regarding current trading prices, ASRT is priced at $0.79, while EBS trades at $9.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas EBS's P/E ratio is 3.53. In terms of profitability, ASRT's ROE is -0.38%, compared to EBS's ROE of +0.27%. Regarding short-term risk, ASRT is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check EBS's competition here
ASRT vs ESPR Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, ESPR has a market cap of 437.4M. Regarding current trading prices, ASRT is priced at $0.79, while ESPR trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas ESPR's P/E ratio is -4.02. In terms of profitability, ASRT's ROE is -0.38%, compared to ESPR's ROE of +0.32%. Regarding short-term risk, ASRT is more volatile compared to ESPR. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check ESPR's competition here
ASRT vs KMDA Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, KMDA has a market cap of 412.9M. Regarding current trading prices, ASRT is priced at $0.79, while KMDA trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas KMDA's P/E ratio is 22.44. In terms of profitability, ASRT's ROE is -0.38%, compared to KMDA's ROE of +0.07%. Regarding short-term risk, ASRT is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check KMDA's competition here
ASRT vs AQST Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, AQST has a market cap of 396.9M. Regarding current trading prices, ASRT is priced at $0.79, while AQST trades at $3.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas AQST's P/E ratio is -5.77. In terms of profitability, ASRT's ROE is -0.38%, compared to AQST's ROE of +1.09%. Regarding short-term risk, ASRT is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check AQST's competition here
ASRT vs ZYBT Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, ZYBT has a market cap of 330.8M. Regarding current trading prices, ASRT is priced at $0.79, while ZYBT trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas ZYBT's P/E ratio is 232.67. In terms of profitability, ASRT's ROE is -0.38%, compared to ZYBT's ROE of +0.04%. Regarding short-term risk, ASRT is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check ZYBT's competition here
ASRT vs CGC Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, CGC has a market cap of 304.5M. Regarding current trading prices, ASRT is priced at $0.79, while CGC trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas CGC's P/E ratio is -0.42. In terms of profitability, ASRT's ROE is -0.38%, compared to CGC's ROE of -0.99%. Regarding short-term risk, ASRT is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check CGC's competition here
ASRT vs ALIM Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ASRT is priced at $0.79, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ASRT's ROE is -0.38%, compared to ALIM's ROE of -0.24%. Regarding short-term risk, ASRT is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check ALIM's competition here
ASRT vs LFCR Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, LFCR has a market cap of 284.3M. Regarding current trading prices, ASRT is priced at $0.79, while LFCR trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas LFCR's P/E ratio is -5.98. In terms of profitability, ASRT's ROE is -0.38%, compared to LFCR's ROE of -2.53%. Regarding short-term risk, ASRT is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check LFCR's competition here
ASRT vs ACB Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, ACB has a market cap of 280.7M. Regarding current trading prices, ASRT is priced at $0.79, while ACB trades at $4.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas ACB's P/E ratio is -124.75. In terms of profitability, ASRT's ROE is -0.38%, compared to ACB's ROE of +0.00%. Regarding short-term risk, ASRT is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check ACB's competition here
ASRT vs LNDC Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ASRT is priced at $0.79, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ASRT's ROE is -0.38%, compared to LNDC's ROE of -10.27%. Regarding short-term risk, ASRT is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check LNDC's competition here
ASRT vs TKNO Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, TKNO has a market cap of 254.2M. Regarding current trading prices, ASRT is priced at $0.79, while TKNO trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas TKNO's P/E ratio is -12.18. In terms of profitability, ASRT's ROE is -0.38%, compared to TKNO's ROE of -0.27%. Regarding short-term risk, ASRT is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check TKNO's competition here
ASRT vs TYHT Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ASRT is priced at $0.79, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ASRT's ROE is -0.38%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ASRT is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check TYHT's competition here
ASRT vs OGI Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, OGI has a market cap of 214.2M. Regarding current trading prices, ASRT is priced at $0.79, while OGI trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas OGI's P/E ratio is 160.00. In terms of profitability, ASRT's ROE is -0.38%, compared to OGI's ROE of +0.02%. Regarding short-term risk, ASRT is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check OGI's competition here
ASRT vs IRWD Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, IRWD has a market cap of 206.3M. Regarding current trading prices, ASRT is priced at $0.79, while IRWD trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas IRWD's P/E ratio is -25.40. In terms of profitability, ASRT's ROE is -0.38%, compared to IRWD's ROE of +0.03%. Regarding short-term risk, ASRT is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check IRWD's competition here
ASRT vs SXTC Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, SXTC has a market cap of 182.2M. Regarding current trading prices, ASRT is priced at $0.79, while SXTC trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas SXTC's P/E ratio is -0.68. In terms of profitability, ASRT's ROE is -0.38%, compared to SXTC's ROE of +0.17%. Regarding short-term risk, ASRT is more volatile compared to SXTC. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check SXTC's competition here
ASRT vs DERM Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, DERM has a market cap of 182.1M. Regarding current trading prices, ASRT is priced at $0.79, while DERM trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas DERM's P/E ratio is -20.19. In terms of profitability, ASRT's ROE is -0.38%, compared to DERM's ROE of -0.49%. Regarding short-term risk, ASRT is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check DERM's competition here
ASRT vs REPH Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ASRT is priced at $0.79, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas REPH's P/E ratio is -8.04. In terms of profitability, ASRT's ROE is -0.38%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ASRT is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check REPH's competition here
ASRT vs BIOA Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, BIOA has a market cap of 165.3M. Regarding current trading prices, ASRT is priced at $0.79, while BIOA trades at $4.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas BIOA's P/E ratio is -0.68. In terms of profitability, ASRT's ROE is -0.38%, compared to BIOA's ROE of -0.25%. Regarding short-term risk, ASRT is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check BIOA's competition here
ASRT vs THTX Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, THTX has a market cap of 149.9M. Regarding current trading prices, ASRT is priced at $0.79, while THTX trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas THTX's P/E ratio is -17.16. In terms of profitability, ASRT's ROE is -0.38%, compared to THTX's ROE of +0.38%. Regarding short-term risk, ASRT is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check THTX's competition here
ASRT vs SCTL Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ASRT is priced at $0.79, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ASRT's ROE is -0.38%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ASRT is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check SCTL's competition here
ASRT vs PROC Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, PROC has a market cap of 114M. Regarding current trading prices, ASRT is priced at $0.79, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas PROC's P/E ratio is 1.53. In terms of profitability, ASRT's ROE is -0.38%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ASRT is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check PROC's competition here
ASRT vs OPTN Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ASRT is priced at $0.79, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ASRT's ROE is -0.38%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, ASRT is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check OPTN's competition here
ASRT vs CRDL Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, CRDL has a market cap of 96.7M. Regarding current trading prices, ASRT is priced at $0.79, while CRDL trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas CRDL's P/E ratio is -3.34. In terms of profitability, ASRT's ROE is -0.38%, compared to CRDL's ROE of -2.10%. Regarding short-term risk, ASRT is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check CRDL's competition here
ASRT vs ZOM Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ASRT is priced at $0.79, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ASRT's ROE is -0.38%, compared to ZOM's ROE of -0.52%. Regarding short-term risk, ASRT is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check ZOM's competition here
ASRT vs INCR Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, INCR has a market cap of 91.6M. Regarding current trading prices, ASRT is priced at $0.79, while INCR trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas INCR's P/E ratio is -3.82. In terms of profitability, ASRT's ROE is -0.38%, compared to INCR's ROE of -0.15%. Regarding short-term risk, ASRT is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check INCR's competition here
ASRT vs GRVI Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ASRT is priced at $0.79, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ASRT's ROE is -0.38%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, ASRT is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check GRVI's competition here
ASRT vs ZYNE Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ASRT is priced at $0.79, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ASRT's ROE is -0.38%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ASRT is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check ZYNE's competition here
ASRT vs QNTM Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, QNTM has a market cap of 68.9M. Regarding current trading prices, ASRT is priced at $0.79, while QNTM trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas QNTM's P/E ratio is -1.59. In terms of profitability, ASRT's ROE is -0.38%, compared to QNTM's ROE of -2.90%. Regarding short-term risk, ASRT is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check QNTM's competition here
ASRT vs SSIC Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ASRT is priced at $0.79, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ASRT's ROE is -0.38%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, ASRT is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check SSIC's competition here
ASRT vs KALA Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, KALA has a market cap of 64.7M. Regarding current trading prices, ASRT is priced at $0.79, while KALA trades at $9.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas KALA's P/E ratio is -1.55. In terms of profitability, ASRT's ROE is -0.38%, compared to KALA's ROE of -6.86%. Regarding short-term risk, ASRT is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check KALA's competition here
ASRT vs VLNS Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ASRT is priced at $0.79, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ASRT's ROE is -0.38%, compared to VLNS's ROE of N/A. Regarding short-term risk, ASRT is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check VLNS's competition here
ASRT vs DRRX Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, DRRX has a market cap of 59.6M. Regarding current trading prices, ASRT is priced at $0.79, while DRRX trades at $1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas DRRX's P/E ratio is -4.47. In terms of profitability, ASRT's ROE is -0.38%, compared to DRRX's ROE of -0.71%. Regarding short-term risk, ASRT is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check DRRX's competition here
ASRT vs JUPW Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ASRT is priced at $0.79, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ASRT's ROE is -0.38%, compared to JUPW's ROE of -0.32%. Regarding short-term risk, ASRT is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check JUPW's competition here
ASRT vs CPIX Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, CPIX has a market cap of 49.2M. Regarding current trading prices, ASRT is priced at $0.79, while CPIX trades at $3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas CPIX's P/E ratio is -14.95. In terms of profitability, ASRT's ROE is -0.38%, compared to CPIX's ROE of -0.11%. Regarding short-term risk, ASRT is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check CPIX's competition here
ASRT vs EGRX Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, EGRX has a market cap of 41.4M. Regarding current trading prices, ASRT is priced at $0.79, while EGRX trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas EGRX's P/E ratio is 3.75. In terms of profitability, ASRT's ROE is -0.38%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, ASRT is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check EGRX's competition here
ASRT vs RMTI Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, RMTI has a market cap of 39.3M. Regarding current trading prices, ASRT is priced at $0.79, while RMTI trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas RMTI's P/E ratio is -16.29. In terms of profitability, ASRT's ROE is -0.38%, compared to RMTI's ROE of -0.07%. Regarding short-term risk, ASRT is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check RMTI's competition here
ASRT vs QLI Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ASRT is priced at $0.79, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas QLI's P/E ratio is -4.92. In terms of profitability, ASRT's ROE is -0.38%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ASRT is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check QLI's competition here
ASRT vs SCYX Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, SCYX has a market cap of 34.2M. Regarding current trading prices, ASRT is priced at $0.79, while SCYX trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas SCYX's P/E ratio is -2.04. In terms of profitability, ASRT's ROE is -0.38%, compared to SCYX's ROE of -0.37%. Regarding short-term risk, ASRT is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check SCYX's competition here
ASRT vs HEXO Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ASRT is priced at $0.79, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ASRT's ROE is -0.38%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ASRT is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check HEXO's competition here
ASRT vs COSM Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, COSM has a market cap of 25.1M. Regarding current trading prices, ASRT is priced at $0.79, while COSM trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas COSM's P/E ratio is -0.81. In terms of profitability, ASRT's ROE is -0.38%, compared to COSM's ROE of -0.55%. Regarding short-term risk, ASRT is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check COSM's competition here
ASRT vs CYTH Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ASRT is priced at $0.79, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ASRT's ROE is -0.38%, compared to CYTH's ROE of +3.20%. Regarding short-term risk, ASRT is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check CYTH's competition here
ASRT vs IXHL Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, IXHL has a market cap of 17.3M. Regarding current trading prices, ASRT is priced at $0.79, while IXHL trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas IXHL's P/E ratio is -0.48. In terms of profitability, ASRT's ROE is -0.38%, compared to IXHL's ROE of -3.57%. Regarding short-term risk, ASRT is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check IXHL's competition here
ASRT vs ACRX Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ASRT is priced at $0.79, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ASRT's ROE is -0.38%, compared to ACRX's ROE of -1.51%. Regarding short-term risk, ASRT is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check ACRX's competition here
ASRT vs PRPH Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, PRPH has a market cap of 13.7M. Regarding current trading prices, ASRT is priced at $0.79, while PRPH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas PRPH's P/E ratio is -0.16. In terms of profitability, ASRT's ROE is -0.38%, compared to PRPH's ROE of -2.30%. Regarding short-term risk, ASRT is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check PRPH's competition here
ASRT vs AYTU Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, AYTU has a market cap of 13.6M. Regarding current trading prices, ASRT is priced at $0.79, while AYTU trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas AYTU's P/E ratio is -1.48. In terms of profitability, ASRT's ROE is -0.38%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, ASRT is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check AYTU's competition here
ASRT vs GELS Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, GELS has a market cap of 12.9M. Regarding current trading prices, ASRT is priced at $0.79, while GELS trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas GELS's P/E ratio is -3.69. In terms of profitability, ASRT's ROE is -0.38%, compared to GELS's ROE of -0.07%. Regarding short-term risk, ASRT is more volatile compared to GELS. This indicates potentially higher risk in terms of short-term price fluctuations for ASRT.Check GELS's competition here
ASRT vs TXMD Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, TXMD has a market cap of 12.7M. Regarding current trading prices, ASRT is priced at $0.79, while TXMD trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas TXMD's P/E ratio is -22.00. In terms of profitability, ASRT's ROE is -0.38%, compared to TXMD's ROE of -0.02%. Regarding short-term risk, ASRT is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check TXMD's competition here
ASRT vs FLGC Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, FLGC has a market cap of 12M. Regarding current trading prices, ASRT is priced at $0.79, while FLGC trades at $21.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas FLGC's P/E ratio is -0.60. In terms of profitability, ASRT's ROE is -0.38%, compared to FLGC's ROE of -2.98%. Regarding short-term risk, ASRT is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check FLGC's competition here
ASRT vs AGRX Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ASRT is priced at $0.79, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ASRT's ROE is -0.38%, compared to AGRX's ROE of +0.66%. Regarding short-term risk, ASRT is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check AGRX's competition here
ASRT vs BFRI Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, BFRI has a market cap of 10.1M. Regarding current trading prices, ASRT is priced at $0.79, while BFRI trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas BFRI's P/E ratio is -0.52. In terms of profitability, ASRT's ROE is -0.38%, compared to BFRI's ROE of -11.51%. Regarding short-term risk, ASRT is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check BFRI's competition here
ASRT vs TLPH Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, TLPH has a market cap of 10.1M. Regarding current trading prices, ASRT is priced at $0.79, while TLPH trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas TLPH's P/E ratio is -1.26. In terms of profitability, ASRT's ROE is -0.38%, compared to TLPH's ROE of -1.51%. Regarding short-term risk, ASRT is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check TLPH's competition here
ASRT vs EVOK Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, EVOK has a market cap of 8.6M. Regarding current trading prices, ASRT is priced at $0.79, while EVOK trades at $5.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas EVOK's P/E ratio is -4.42. In terms of profitability, ASRT's ROE is -0.38%, compared to EVOK's ROE of -0.99%. Regarding short-term risk, ASRT is less volatile compared to EVOK. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check EVOK's competition here
ASRT vs SNOA Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, SNOA has a market cap of 8.4M. Regarding current trading prices, ASRT is priced at $0.79, while SNOA trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas SNOA's P/E ratio is -2.30. In terms of profitability, ASRT's ROE is -0.38%, compared to SNOA's ROE of -0.76%. Regarding short-term risk, ASRT is less volatile compared to SNOA. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check SNOA's competition here
ASRT vs NLTX Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ASRT is priced at $0.79, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ASRT's ROE is -0.38%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ASRT is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check NLTX's competition here
ASRT vs BFRIW Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, BFRIW has a market cap of 7.6M. Regarding current trading prices, ASRT is priced at $0.79, while BFRIW trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas BFRIW's P/E ratio is -0.07. In terms of profitability, ASRT's ROE is -0.38%, compared to BFRIW's ROE of -11.51%. Regarding short-term risk, ASRT is less volatile compared to BFRIW. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check BFRIW's competition here
ASRT vs LCI Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ASRT is priced at $0.79, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas LCI's P/E ratio is -0.04. In terms of profitability, ASRT's ROE is -0.38%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ASRT is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check LCI's competition here
ASRT vs BGXX Comparison August 2025
ASRT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASRT stands at 75.6M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, ASRT is priced at $0.79, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASRT currently has a P/E ratio of -1.75, whereas BGXX's P/E ratio is -0.76. In terms of profitability, ASRT's ROE is -0.38%, compared to BGXX's ROE of -0.35%. Regarding short-term risk, ASRT is less volatile compared to BGXX. This indicates potentially lower risk in terms of short-term price fluctuations for ASRT.Check BGXX's competition here